Iterum Therapeutics plc – NASDAQ:ITRM

Add to watchlist

$0.86

-1.04

-54.74%

Market closed

Open in 2 days

+15.85%

month

+15.85%

quarter

-1.55%

year

Market Cap	49.25M
Enterprise value	1.00M

P/E	-0.28
EV/Sales	N/A
EV/EBITDA	-0.02
Price/Sales	N/A
Price/Book	0.42
PEG ratio	N/A
EPS	-2.65

Revenue	N/A
EBITDA	-43.66M
Income	-35.58M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Iterum Therapeutics plc (NASDAQ:ITRM): Profit margin
Jun 2023	0	-12.24M
Sep 2023	0	-3.87M
Dec 2023	2.62M	-12.36M	-471.83%
Mar 2024	0	-7.10M

Iterum Therapeutics Financials Estimate

Q Y

Iterum Therapeutics plc (NASDAQ:ITRM): Analyst Estimates
2025	12.13M	-18.46M	-152.24%
2026	26.15M	-12.39M	-47.4%
2027	44.63M	-4.73M	-10.6%
2028	69.37M	4.40M	6.35%

Analysts Price target
Financials & Ratios estimates

Iterum Therapeutics plc (NASDAQ:ITRM): Earnings per share (EPS)
2023-11-14	-0.91	-0.3
2024-03-28	-1.02	-0.94

Iterum Therapeutics plc (NASDAQ:ITRM): Debt to assets
Jun 2023	51021000	43.89M	86.03%
Sep 2023	39728000	36.29M	91.36%
Dec 2023	26259000	32.66M	124.38%
Mar 2024	19625000	25.77M	131.34%

Iterum Therapeutics plc (NASDAQ:ITRM): Cash Flow
Jun 2023	-7.63M	4.34M	200K
Sep 2023	-9.26M	360K	10K
Dec 2023	-12.45M	13.33M	580.55K
Mar 2024	-13.08M	7.21M	7.21M

Iterum Therapeutics alternative data

Iterum Therapeutics plc (NASDAQ:ITRM): Employee count
Aug 2023	14
Sep 2023	14
Oct 2023	14
Nov 2023	14
Dec 2023	14
Jan 2024	14
Feb 2024	14
Mar 2024	14
Apr 2024	14
May 2024	14
Jun 2024	14
Jul 2024	14

Iterum Therapeutics
Hedge Funds Holdings Q1 2023

1.41% -0.96%

of ITRM is owned by hedge funds

13 -6

hedge funds hold ITRM stock

172.50K -117.17K

shares is hold by hedge funds

ITRM hedge funds holdings changes

Iterum Therapeutics
Insider Trading

Iterum Therapeutics plc (NASDAQ:ITRM): Insider trades (number of shares)
Period	Buy	Sel
Nov 2023	30000	0
Dec 2023	35000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	22 Dec 2023	DUNNE MICHAEL W. director	Ordinary Shares	25,000	$1.4	$35,000
Purchase	18 Dec 2023	DUNNE MICHAEL W. director	Ordinary Shares	10,000	$1.84	$18,440
Option	1 Dec 2023	PUTTAGUNTA SAILAJA officer: Chief Medical Officer officer: Chief Medical Officer	Restricted Share Units	8,333	N/A	N/A
Purchase	22 Nov 2023	DUNNE MICHAEL W. director	Ordinary Shares	20,000	$2.04	$40,700
Purchase	20 Nov 2023	FISHMAN COREY N. director, officer..	Ordinary Shares	10,000	$1.59	$15,860
Option	1 Oct 2023	DUNNE MICHAEL W. director	Restricted Share Units	3,487	N/A	N/A
Option	1 Oct 2023	HUNT RONALD director director	Ordinary Shares	5,479	N/A	N/A
Option	1 Oct 2023	HUNT RONALD director director	Restricted Share Units	5,479	N/A	N/A
Option	1 Oct 2023	DUNNE MICHAEL W. director	Ordinary Shares	3,487	N/A	N/A
Option	1 Jul 2023	DUNNE MICHAEL W. director	Ordinary Shares	1,779	N/A	N/A

ITRM insider trading transactions

Iterum Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 13 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 14 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 11 Aug 2023	Q2 2023 Earnings Call Transcript

ITRM earnings call transcripts

Iterum Therapeutics
Executives

Insider	Age	Compensation
Mr. Corey N. Fishman (1965) Pres, Chief Executive Officer & Director	60	$1,070,000
Ms. Judith M. Matthews (1970) Chief Financial Officer	55	$606,140
Dr. Michael W. Dunne M.D. (1960) Strategic Advisor & Director	65	$561,680

Iterum Therapeutics
Latest News

Thursday, 21 November 2024
08:30	Iterum Therapeutics Regains Full Nasdaq Compliance	globenewswire.com
Thursday, 14 November 2024
13:14	Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript	seekingalpha.com
07:00	Iterum Therapeutics Reports Third Quarter 2024 Financial Results	globenewswire.com
Monday, 28 October 2024
10:27	Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)	seekingalpha.com
05:00	Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections	prnewswire.com
Friday, 25 October 2024
11:03	Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections	globenewswire.com
Thursday, 10 October 2024
08:30	Iterum Therapeutics to Present Data at IDWeek 2024	globenewswire.com
Wednesday, 9 October 2024
17:00	Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit	globenewswire.com
Wednesday, 11 September 2024
13:05	ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down	zacks.com
Friday, 6 September 2024
16:30	Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference	globenewswire.com
Friday, 16 August 2024
11:27	Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 14 August 2024
07:00	Iterum Therapeutics Reports Second Quarter 2024 Financial Results	globenewswire.com
Wednesday, 7 August 2024
16:30	Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024	globenewswire.com
Tuesday, 6 August 2024
17:30	Iterum Therapeutics Announces Expiration and Results of Rights Offering	globenewswire.com
Friday, 2 August 2024
08:00	Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem	globenewswire.com
Monday, 22 July 2024
07:30	Iterum Therapeutics Commences Rights Offering	globenewswire.com
Friday, 21 June 2024
08:00	Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections	globenewswire.com
Friday, 31 May 2024
08:00	Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections	globenewswire.com
Monday, 13 May 2024
07:00	Iterum Therapeutics Reports First Quarter 2024 Financial Results	globenewswire.com
Monday, 6 May 2024
08:00	Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024	globenewswire.com
Monday, 29 April 2024
08:00	Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	globenewswire.com
Thursday, 28 March 2024
10:08	Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript	Seeking Alpha
Thursday, 21 March 2024
16:30	Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	GlobeNewsWire
Thursday, 7 March 2024
09:00	Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up	Zacks Investment Research
Tuesday, 7 November 2023
08:30	Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023	GlobeNewsWire
Thursday, 12 October 2023
09:15	Iterum Therapeutics to Present Data at IDWeek 2023	GlobeNewsWire
Friday, 4 August 2023
17:00	Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023	GlobeNewsWire
Monday, 12 June 2023
18:23	Iterum Therapeutics to Present Data at ASM Microbe 2023	GlobeNewsWire
Thursday, 13 April 2023
13:39	All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy	Zacks Investment Research
Thursday, 9 March 2023
17:00	Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Iterum Therapeutics stock today?

One share of Iterum Therapeutics stock can currently be purchased for approximately $0.86.
When is Iterum Therapeutics's next earnings date?

Unfortunately, Iterum Therapeutics's (ITRM) next earnings date is currently unknown.
Does Iterum Therapeutics pay dividends?

No, Iterum Therapeutics does not pay dividends.
How much money does Iterum Therapeutics make?

Iterum Therapeutics has a market capitalization of 49.25M. Iterum Therapeutics made a loss 38.37M US dollars in net income (profit) last year or -$0.94 on an earnings per share basis.
What is Iterum Therapeutics's stock symbol?

Iterum Therapeutics plc is traded on the NASDAQ under the ticker symbol "ITRM".
What is Iterum Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Iterum Therapeutics?

Shares of Iterum Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Iterum Therapeutics's key executives?
Iterum Therapeutics's management team includes the following people:
- Mr. Corey N. Fishman Pres, Chief Executive Officer & Director(age: 60, pay: $1,070,000)
- Ms. Judith M. Matthews Chief Financial Officer(age: 55, pay: $606,140)
- Dr. Michael W. Dunne M.D. Strategic Advisor & Director(age: 65, pay: $561,680)
How many employees does Iterum Therapeutics have?

As Jul 2024, Iterum Therapeutics employs 14 workers.
When Iterum Therapeutics went public?

Iterum Therapeutics plc is publicly traded company for more then 7 years since IPO on 25 May 2018.
What is Iterum Therapeutics's official website?

The official website for Iterum Therapeutics is iterumtx.com.
How can i contact Iterum Therapeutics?

Iterum Therapeutics can be reached via phone at +353 1 669 4820.

Iterum Therapeutics plc

iterumtx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

+353 1 669 4820

Fitzwilliam Court
Dublin, 2

CIK: 0001659323
ISIN: IE000TTOOBX0
CUSIP: G6333L101